Advances in Biologic Therapies for Allergic Diseases: Current Trends, Emerging Agents, and Future Perspectives
Journal of Clinical Medicine · 08.02.2025 · 14 (4) · 1079
DOI: 10.3390/jcm14041079 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 08.02.2025. Verfasst von Ewa Alska und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Allergology, Clinical Immunology and Internal Diseases, Collegium Medicum Bydgoszcz, Nicolaus Copernicus University Torun, 85-067 Bydgo…. Die Arbeit wurde bisher 40-mal zitiert (Crossref) und nennt 229 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Biologic therapies have revolutionized the treatment of severe allergic diseases, including asthma, atopic dermatitis (AD), chronic spontaneous urticaria (CSU), chronic rhinosinusitis with nasal polyps (CRSwNP), eosinophilic gastrointestinal diseases (EGIDs), and allergic rhinitis (AR). These molecularly targeted agents provide significant benefits for patients unresponsive to conventional treatments by addressing underlying immune mechanisms, particularly type 2 inflammation driven by cytokines such as IL-4, IL-5, and IL-13. Recent advancements include biologics targeting alarmins like thymic stromal lymphopoietin (TSLP) and IL-33, which may address both type 2 and non-type 2 inflammation, broadening their therapeutic scope. Despite their effectiveness, biologics remain expensive, posing socioeconomic challenges, and there are concerns regarding long-term safety and inter-individual variability in responses. Promising innovations such as bispecific antibodies and ultra-long-acting agents are under investigation, alongside digital health tools like remote biomarker monitoring and AI-driven decision support systems, which aim to enhance personalized care. However, disparities in access, particularly for underserved populations, underscore the need for policy reforms and affordable biosimilars. This review synthesizes recent findings and emerging trends, highlighting the evolving role of biologics in transforming allergic disease management and offering insights into future research directions.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Allergology, Clinical Immunology and Internal Diseases, Collegium Medicum Bydgoszcz, Nicolaus Copernicus University Torun, 85-067 Bydgoszcz, Poland.
- Student Research Club of Clinical Immunology, Department of Allergology, Clinical Immunology and Internal Diseases, Collegium Medicum Bydgoszcz, Nicolaus Copernicus University Torun, 85-067 Bydgoszcz, Poland.
ORCID-Profile: Dariusz Łaszczych, Katarzyna Napiórkowska-Baran, Bartłomiej Szymczak, Alicja Rajewska, Zbigniew Bartuzi
Zitieren
APA
Alska, E., Łaszczych, D., Napiórkowska-Baran, K., Szymczak, B., Rajewska, A., Rubisz, A. E., Romaniuk, P., Wrzesień, K., Mućka, N., & Bartuzi, Z. (2025). Advances in Biologic Therapies for Allergic Diseases: Current Trends, Emerging Agents, and Future Perspectives. Journal of Clinical Medicine, 14(4), 1079. https://doi.org/10.3390/jcm14041079
Vancouver
Alska E, Łaszczych D, Napiórkowska-Baran K, Szymczak B, Rajewska A, Rubisz AE, et al. Advances in Biologic Therapies for Allergic Diseases: Current Trends, Emerging Agents, and Future Perspectives. Journal of Clinical Medicine. 2025;14(4):1079. doi:10.3390/jcm14041079
BibTeX
@article{Alska2025,
author = {Alska, Ewa and Łaszczych, Dariusz and Napiórkowska-Baran, Katarzyna and Szymczak, Bartłomiej and Rajewska, Alicja and Rubisz, Aleksandra Ewa and Romaniuk, Paulina and Wrzesień, Katarzyna and Mućka, Natalia and Bartuzi, Zbigniew},
title = {Advances in Biologic Therapies for Allergic Diseases: Current Trends, Emerging Agents, and Future Perspectives},
journal = {Journal of Clinical Medicine},
year = {2025},
volume = {14},
number = {4},
pages = {1079},
doi = {10.3390/jcm14041079}
}
EUVIMED